



Press release from Emotra AB (publ)

Göteborg, March 25, 2020

Emotra has signed a collaboration agreement for clinical studies with Linköping University

Lately, Emotra has been focusing on the indication area depression relapse, with the goal of starting a clinical study in 2020. We have now reached an important milestone with the signing of a collaboration agreement with Linköping University, through which we will be employing the services of professor Toomas Timpka to document the connection between hyporeactivity and depression relapse.

The aim of this agreement is to gain access to a researcher with knowledge and experience of planning larger studies, and who is also able to see a project through to publication. The formal agreement is between Emotra and Linköping University and primarily encompasses planning, development of a study protocol, as well as management and processing of the study data. These tasks are crucial for assuring the Company's access to high-quality data that can be published. As previously communicated, we have already signed a collaboration agreement with the University of Warsaw for the same project.

Toomas Timpka is a professor and attending physician at the Department of Health, Medicine and Caring Sciences (HMV) as well as the Division of Society and Health (SH), where he conducts research in athletic medicine, epidemiology, prediction and control of infectious diseases, and information sciences. Toomas is a psychiatrist and has, among other things, studied the mental health of young athletes. He will now start planning a study that is designed to specifically examine the connection between hyporeactivity and depression relapse.

"I am very pleased that we have managed to find someone as experienced as professor Toomas Timpka and that we have reached an agreement with Linköping University that provides us with access to his time. Planning and carrying out clinical studies require a great deal of things being in place. Both the university's research infrastructure and professor Timpka's know-how are crucial for assuring our access to high-quality data. In this context, Emotra will act as the entity ordering the study, the supplier of the technology and test analyses, while the researchers will be in charge of the scientific process," says Daniel Poté, Emotra AB's CEO.

For further information about Emotra, please contact:

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se

This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on March 25, 2020, under the above contact's supervision.

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR[®], is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.